Full-Time

Scientist – Aging Metabolism

Confirmed live in the last 24 hours

Calico Labs

Calico Labs

201-500 employees

Research and develop treatments for aging

Biotechnology
Healthcare

Compensation Overview

$127k - $155kAnnually

+ Annual Cash Bonuses

Entry

San Bruno, CA, USA

Must work onsite five days per week.

Category
Biology Lab & Research
Biology & Biotech
Requirements
  • PhD or MD/PhD in cell/molecular biology, biochemistry or a related field with 0-5 years of postdoctoral and/or industry experience
  • Experience working with animal models to study human disease and/or aging
  • Deep knowledge of cellular and organismal metabolism and physiology
  • Strong working knowledge of genetics, cell biology and molecular genetics
  • Detail-oriented, organized and driven
  • A track record of strong research productivity
  • Strong teamwork and communication skills
  • Flexible, able to respond quickly to shifting priorities and able to multitask
  • Must be willing to work onsite five days per week
Responsibilities
  • Perform basic research to determine metabolic mechanisms underlying aging process
  • Develop approaches to evaluate metabolic interactions between specific cell types during aging
  • Publish papers and present findings both internally and at scientific conferences

Calico Labs focuses on researching the biology of aging and creating treatments for age-related diseases. The company conducts scientific research to understand how aging works and the diseases that come with it. By collaborating with academic institutions and other biopharmaceutical companies, Calico Labs uses advanced technologies to drive research and develop practical medical solutions. This collaborative approach helps speed up research and increases the chances of making important discoveries in aging. Calico Labs earns revenue through partnerships, joint research projects, and potential licensing of its technologies. The main goal is to contribute significantly to the understanding and treatment of aging.

Company Stage

Seed

Total Funding

$2M

Headquarters

South San Francisco, California

Founded

2013

Growth & Insights
Headcount

6 month growth

3%

1 year growth

3%

2 year growth

3%
Simplify Jobs

Simplify's Take

What believers are saying

  • The inclusion of fosigotifator in the FDA's START Pilot Program highlights Calico Labs' potential to develop groundbreaking treatments for rare diseases.
  • Extending the collaboration with the Broad Institute until 2029 ensures continued progress in understanding aging and developing therapies for age-related neurodegeneration.
  • The appointment of renowned experts like Michael Lenardo, M.D., as Chief Scientific Officer strengthens Calico Labs' leadership and scientific expertise.

What critics are saying

  • The highly specialized focus on aging and age-related diseases may limit the company's market opportunities compared to broader biopharmaceutical firms.
  • Dependence on strategic partnerships and collaborations could pose risks if these alliances face challenges or dissolve.

What makes Calico Labs unique

  • Calico Labs focuses exclusively on the biology of aging and age-related diseases, setting it apart from other biopharmaceutical companies with broader research scopes.
  • Their strategic partnerships with leading academic institutions and biopharmaceutical firms, such as the Broad Institute and AbbVie, enhance their research capabilities and accelerate innovation.
  • Calico Labs' emphasis on interdisciplinary collaboration and advanced technologies fosters a unique research environment that drives significant scientific discoveries.

Help us improve and share your feedback! Did you find this helpful?